Dual‐Targeted M1 Macrophage Extracellular Vesicles Reprogram the Tumor Microenvironment and Enhance Natural Killer Cell Immunotherapy in Breast Cancer
Journal of Extracellular Vesicles · 2026
DOI: 10.1002/jev2.70379 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Extracellular Vesicles, 2026. Verfasst von Su Jin Kang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioengineering and Nano-Bioengineering, Incheon National University, Incheon, South Korea. Hauptthemen laut MEDLINE: Killer Cells, Natural, Tumor Microenvironment, Breast Neoplasms, Immunotherapy. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Korea Polar Research Institute.
Abstract (Originalsprache)
Breast cancer is the most commonly diagnosed cancer worldwide and a leading cause of cancer‐related mortality in women. Despite therapeutic advances, treating advanced or recurrent cases is substantially hampered by drug resistance and the immunosuppressive tumor microenvironment (TME). Here, we report a breakthrough immunotherapeutic strategy using dual‐targeted extracellular vesicles from pro‐inflammatory M1 macrophages, hyaluronic acid (HA), and cyclic RGD (M1EV_HA/cRGD), which function as molecular bridges to physically link natural killer (NK) cells with cancer cells. Our platform simultaneously reprograms the hostile TME while activating potent antitumor immunity. HA is incorporated to engage CD44 receptors on NK cells and cRGD peptides to bind tumor‐overexpressing integrins, establishing precision dual‐targeting. M1EV_HA/cRGD could physically tether NK cells directly to tumors, and deliver inflammatory cytokines and miRNAs that transform the immunosuppressive TME into a pro‐inflammatory battlefield, substantially amplifying immune activation. In vitro and in vivo studies demonstrate that M1EV_HA/cRGD significantly enhances NK cell clustering at tumor sites, activation status, and cytotoxic killing of breast cancer cells. Unlike single‐targeted approaches, this dual‐targeting mechanism achieves simultaneous TME reprogramming and enhanced immune‐tumor engagement. M1EV_HA/cRGD is a paradigm shift in solid tumor immunotherapy that directly addresses breast cancer treatment failure, can overcome therapeutic resistance, and substantially improve patient survival outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Bioengineering and Nano-Bioengineering, Incheon National University, Incheon, South Korea.
- Division of Bioengineering, Incheon National University, Incheon, South Korea.
- Research Center for Bio Materials & Process Development, Incheon National University, Incheon, South Korea.
- Integrated Major in Bio-manufacturing AX, Incheon National University, Incheon, South Korea.
Förderung
- National Research Foundation of Korea
- Korea Polar Research Institute
Zitieren
APA
Kang, S. J., Baek, G., Ju, S., Kim, G., Gwak, S., & Rhee, W. J. (2026). Dual‐Targeted M1 Macrophage Extracellular Vesicles Reprogram the Tumor Microenvironment and Enhance Natural Killer Cell Immunotherapy in Breast Cancer. Journal of Extracellular Vesicles. https://doi.org/10.1002/jev2.70379
Vancouver
Kang SJ, Baek G, Ju S, Kim G, Gwak S, Rhee WJ. Dual‐Targeted M1 Macrophage Extracellular Vesicles Reprogram the Tumor Microenvironment and Enhance Natural Killer Cell Immunotherapy in Breast Cancer. Journal of Extracellular Vesicles. 2026. doi:10.1002/jev2.70379
BibTeX
@article{Kang2026,
author = {Kang, Su Jin and Baek, Gichan and Ju, Suwun and Kim, Gunhee and Gwak, Seongjin and Rhee, Won Jong},
title = {Dual‐Targeted M1 Macrophage Extracellular Vesicles Reprogram the Tumor Microenvironment and Enhance Natural Killer Cell Immunotherapy in Breast Cancer},
journal = {Journal of Extracellular Vesicles},
year = {2026},
doi = {10.1002/jev2.70379}
}
EUVIMED